Thomas Blevins, MD
Endocrinology, Diabetes & Metabolism · Austin, TXNPI 1114992088
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $756,516 of the $903,937 with a category attached, or 83.7%. 56 manufacturers reported payments, led by Lilly USA, LLC at 41.6% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,404 payments — averaging $643.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$376K
- Sanofi-aventis U.S. LLC$120K
- Novo Nordisk$90K
- Boehringer Ingelheim$45K
- AstraZeneca$39K
- Dexcom, Inc.$28K
- plus $206K from 50 others
Across 1,469 payments — averaging $4590.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3M
- Dexcom, Inc.$793K
- AbbVie$712K
- Boehringer Ingelheim$510K
- Tandem Diabetes Care, Inc.$330K
- Mannkind Corporation$294K
- plus $1.1M from 11 others
What the payments were for
- Consulting fees$97,33111%
- Speaking & faculty fees$756,51684%
- Travel & lodging$30,4263%
- Food & beverage$19,4782%
- Education$1870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$139,168
- TZIELD$82,337
- JARDIANCE$79,936
- TRULICITY$78,004
- Ozempic$44,945
- RYBELSUS$40,566
- FARXIGA$37,853
- AFREZZA$21,073
- Eversense$20,673
- Vascepa$20,400
- HUMULIN$20,200
- t:slim X2 Insulin Pump with Control-IQ$19,971
- DEXCOM G7 GSS (161)$19,472
- SOLIQUA 100/33$16,322
- INVOKANA$12,182
- EYLEA$11,805
- Omnipod$11,250
- STEGLATRO$9,341
- LYUMJEV$8,950
- DEXCOM G6 TRANSMITTER$8,426
How this compares
$903,937 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 393 | $533,540 |
| OzempicSemaglutide | 353 | $494,730 |
| TrulicityDulaglutide | 266 | $399,443 |
| JardianceEmpagliflozin | 273 | $348,929 |
| FarxigaDapagliflozin Propanediol | 206 | $209,831 |
| ForteoTeriparatide | 17 | $141,952 |
| Teriparatide | 54 | $114,768 |
| Repatha SureclickEvolocumab | 105 | $95,013 |
| Tresiba Flextouch U-100Insulin Degludec | 95 | $72,561 |
| SynthroidLevothyroxine Sodium | 679 | $63,428 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $56,812 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $52,589 |
| AfrezzaInsulin Regular, Human | 20 | $49,187 |
| Humalog Kwikpen U-100Insulin Lispro | 115 | $45,603 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $44,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $376,254 | $1,095,034731 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $90,154 | $545,331420 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $44,537 | $376,055289 claims |
| AstraZenecaFarxiga | $38,504 | $209,831206 claims |
| Alvogen IncTeriparatide | $35 | $114,76854 claims |
| AbbVieSynthroid | $244 | $63,428679 claims |
| Mannkind CorporationAfrezza | $21,725 | $49,18720 claims |
| AmgenProlia | $8,282 | $43,39326 claims |
| MerckJanuvia | $9,785 | $35,09632 claims |
| BayerKerendia | $1,544 | $24,88925 claims |
| PfizerGenotropin | $33 | $19,14518 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $17,3001,381 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Austin
- Lindsay HarrisonAustin$103K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.